Methods for treating neuropathy by agonist anti-trk-C...

Chemistry: analytical and immunological testing – Involving production or treatment of antibody

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C436S548000, C424S141100, C424S142100

Reexamination Certificate

active

07615383

ABSTRACT:
The invention concerns agonist anti-trkC monoclonal antibodies which mimic certain biological activities of NT-3, the native ligand of trkC. The invention further concerns the use of such antibodies in the prevention and/or treatment of cellular degeneration, including nerve cell damage associated with acute nervous cell system injury and chronic neurodegenerative diseases, including peripheral neuropathy.

REFERENCES:
patent: 5364769 (1994-11-01), Rosenthal
patent: 5766863 (1998-06-01), Godowski et al.
patent: 5891650 (1999-04-01), Godowski et al.
patent: 5910574 (1999-06-01), Presta et al.
patent: 6015552 (2000-01-01), Watanabe et al.
patent: 6656465 (2003-12-01), Clary et al.
patent: 2004/0137513 (2004-07-01), Devaux et al.
patent: 2007/0036794 (2007-02-01), Devaux et al.
patent: 455460 (1991-11-01), None
patent: 522530 (1993-01-01), None
patent: WO 97/21732 (1997-06-01), None
patent: WO 98/49308 (1998-11-01), None
patent: WO 00/24415 (2000-05-01), None
White et al. Nat Rev. Drug discovery. 2005. 4: 834-844.
Wang et al. Adv. Drug Delivery Rev. 2003. 55:949-965.
Wu et al. J. Mol. Biol. (1999) 294, 151-162.
MacCallum et al. J. Mol. Biol. 1996. 262, 732-745.
Burgess et al. J of Cell Bio. 111:2129-2138, 1990.
Bowie et al. Science, 1990, 247:1306-1310.
Rudikoff et al. Proc. Natl. Acad. Sci. USA 1982 vol. 79: p. 1979.
Pawson et al. 2003, Science 300:445-452.
Barbacid,J. Neurobiol. 25:1386-1403 [1994].
Barbarcid,Ann. New York Acad. Sci. 766:442-458 [1995].
Barde, Y.A. et al.,EMBO J. 1, 549-553 [1982].
Barker, PA,Cell Death Diff. 5:346-356 [1998].
Belliveau et al.,J. Cell. Biol. 136:375-388 [1997].
Berkemeir, et al.,Somat. Cell Mol. Genet. 18(3):233-245 [1992].
Berkemeir, L.R. et al.,Neuron 7, 857-866 [1991].
Capon et al.,Nature337: 525-531 [1989].
Casaccia-Bonnefil, et al.,Cell Death Diff. 5:357-364 [1998].
Carter et al.,Bio/Technology10: 163-167 [1992].
Chaudhry, et al.,Muscle and Nerve 23: 189-192 [2000].
Davies et al. (Neuron 11, 565-574 [1993].
Davies, AM,Curr. Biol. 10:R198-R200 [2000].
Donovan et al.,A.J. Path. 147:309-324 [1995].
Donovan et al.,Nature Genetics 14:210-213 [1996].
Ernfors et al.,Proc. Natl. Acad. Sci. USA 87, 5454-5458 (1990).
Farinas et al.,Neuron 21:325-334 [1998].
Gao et al.,Ann. Neurol. 38(1):30-7 [1995].
Gotz et al.,Nature 372:266-269 [1994].
Haase et al.,J. Neurol. Sci. 160:S97-S105 [1998].
Hallbook, F. et al.,Neuron 6, 845-858 [1991].
Hapner, et al.,Developm. Biol. 201:90-100 [1998].
Helgren et al.,J. Neurosci, 17(1):372-82 [1997].
Henzel et al.,J. Chromatography404: 41-52 [1987].
Herrmann et al.,Mol. Biol. Cell 4, 1205-1216 [1993].
Höhn et al.,Nature 344, 339 [1990].
Hongo et al.,Hybridoma14: 253-260 [1995].
Ip et al.,Proc. Natl. Acad. Sci USA 89, 3060-3064 [1992].
Jones and Reichardt,Proc. Natl. Acad. Sci. USA 87, 8060-8064 (1990).
Kabat and Wu,J. Immunol. 147: 1709-1719 [1991].
Kaisho et al.,FEBS Lett. 266, 187 [1990].
Klein et al.,EMBO J, 8, 3701-3709 [1989].
Kraemer et al.,Arteriol. Thromb. and Vasc. Biol. 19:1041-1050 [1999].
Lai, et al.,Mol. Cell. Neurosci. 11(1-2):64-76 [1998].
Lamballe et al.,Cell 66, 967-979 [1991].
Leibrock, J. et al.Nature 341, 149-152 [1989].
Levi-Montalcini, R. et al, P.U.,Physiol. Rev. 48, 534-569 [1968].
Maisonpierre et al.,Science 247, 1446 [1990].
Martin-Zanca et al.,Mol. Cell. Biol. 9(1):24-33 [1989].
Matsudaira,J. Biol. Chem. 262: 10035-10038 [1987].
Meakin and Shooter,Trends Neurosci. 15, 323-331 [1992].
Middlemas et al.,Mol. Cell. Biol. 11, 143-153 [1991].
Nilsson et al.,FEBS Letters 424(3):285-90 [1998].
Raoul et al.,Curr. Op. Neurobiol. 10:111-117 [2000].
Rodriguez-Tebar et al.,EMBO J. 11, 917-922 [1992].
Rosenthal et al.,Neuron 4, 767 [1990].
Ryden and Ibanez,J. Biol. Chem. 271:5623-5627 [1996].
Sadick et al.,Exp. Cell Res. 234: 354-361 [1997].
Shelton et al.,J. Neurosci. 15: 477-491 [1995].
Thoenen, H. et al.,Rev. Physiol. Biochem. Pharmacol. 109, 145-178 [1987].
Tsoulfas et al.,Neuron10:975-990 [1993].
Ultsch et al.,J. Mol. Biol. 290:149-159 (1999).
Urfer et al.,Biochem. 36:4775-4781 [1997].
Urfer et al.,EMBO J. 14:2795-2805 [1995].
Berkower, I., “The Promise and Pitfalls of Monoclonal Antibody Therapeutics,”Curr. Opi. Biotech., 7: 622-628, 1996.
Hongo, J. et al. “Agonist Monoclonal Antibodies to Human trkC Receptor map to Epitopes Overlapping with NT-3 Binding Site,”Society for Neuroscience Abstracts, 27(1), 2001.
Mendez, M., et al., “Functional Transplant of Megabase Human Immunoglobulin Loci Recapitulates Human Antibody Response in Mice,”Nature Genetics, 15(2): 146-156, 1997.
Peterson, N., et al., “Bacterial Expression and Characterization of Recombinant Biologically Active Anti-Tyrosine Kinase Receptor Antibody Forms,” DNA and Cell Biol., 17: 1031-1040, 1998.
Urfer, R., et al., “High Resolution Mapping of the Binding Site of TrkA for Nerve Growth Factor and TrkC for Neurotrophin-3 on the second Immunologlobulin-like domain on the Trk Receptors,”The Journal of Biological Chemistry, 273(10): 5829-5840, 1998.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Methods for treating neuropathy by agonist anti-trk-C... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for treating neuropathy by agonist anti-trk-C..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating neuropathy by agonist anti-trk-C... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4126351

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.